FDA Approves Oral Daprodustat to Treat Anemia in Dialysis
The FDA approval of daprodustat is based on results from the ASCEND-D trial comparing daprodustat with ESAs.
The FDA approval of daprodustat is based on results from the ASCEND-D trial comparing daprodustat with ESAs.
In both men and women, the prevalence of severe anemia increased as kidney function decreased.
Patients with anemia may know some of the risks associated with the condition, but do they know about potential cancer-related risks? How can health care professionals educate patients on the risks, and what is known about the potential association between newly diagnosed anemia and cancer risk?
Investigators report results from a systematic review and meta-analysis of data from 23 randomized controlled trials involving 15,144 patients with anemia of CKD.
According to investigators, it is crucial to find the underlying causes of post-transplant anemia and to treat all reversible causes.
Investigators compared the therapies in a large national cohort of patients with normal kidney function.
Recent study included 980 individuals older than 65 years who participated in the Cardiovascular Health Study.
Currently, there is no standard regimen for maintenance iron supplementation in patients receiving hemodialysis.
Iron deficiency associates with adverse outcomes in patients on peritoneal dialysis, regardless of anemia status.
Paricalcitol Independently Increases Hemoglobin Levels